JBIO — Jade Biosciences Share Price
0.000.00%
Last trade - 00:00- $401.86m
- $325.65m
- 41
- 14
- 85
- 44
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 5.35 | ||
| Price to Tang. Book | 5.35 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -71.04% | ||
| Return on Equity | -59.01% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Jade Biosciences, Inc. is a biotechnology company, which is focused on developing therapies for autoimmune diseases. The Company’s lead asset, JADE-001, is an investigational anti-A PRoliferation-Inducing Ligand (APRIL) monoclonal antibody for the treatment of Immunoglobulin A (IgA) nephropathy (IgAN), an autoimmune condition in which the kidney is damaged by pathogenic IgA containing immune complexes, leading to proteinuria and kidney function decline, and potentially progressing to end-stage kidney disease requiring dialysis or transplantation. Designed to block the APRIL protein, JADE-001 targets an underlying cause of IgAN, offering the potential to reduce pathogenic IgA levels, decrease proteinuria, and preserve kidney function over the long term. The Company’s pipeline also includes two undisclosed antibody discovery programs: JADE-002 and JADE-003, which are in preclinical development.
Directors
- Mark Iwicki NEC (54)
- Benjamin Dake PRE (45)
- Timothy Noyes CEO (59)
- George Eldridge CFO (58)
- Hunter Gillies OTH (55)
- Ralph Niven OTH (61)
- Allison Dorval IND (46)
- David Grayzel IND (53)
- Maha Katabi IND (47)
- Joshua Resnick IND (46)
- Last Annual
- December 31st, 2024
- Last Interim
- March 31st, 2025
- Incorporated
- April 28th, 2025
- Public Since
- June 30th, 2021
- No. of Shareholders
- 1
- No. of Employees
- 4
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 32,200,000
- Address
- 930 Winter Street, Suite M-500, WALTHAM, 02451
- Web
- https://jadebiosciences.com/
- Phone
- +1 6174432400
- Auditors
- KPMG LLP
Upcoming Events for JBIO
Q2 2025 Aerovate Therapeutics Inc Earnings Release
Similar to JBIO
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
What is the Jade Biosciences share price?
As of Today at 21:25 UTC, shares in Jade Biosciences are trading at $12.48. This share price information is delayed by 15 minutes.
How has the Jade Biosciences share price performed this year?
Shares in Jade Biosciences last closed at $12.48 and the price had moved by -83.55% over the past 365 days. In terms of relative price strength the Jade Biosciences share price has underperformed the S&P500 Index by -85.17% over the past year.
What are the analyst and broker recommendations for Jade Biosciences?
The overall consensus recommendation for Jade Biosciences is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Jade Biosciences dividend yield?
Jade Biosciences does not currently pay a dividend.
Does Jade Biosciences pay a dividend?
Jade Biosciences does not currently pay a dividend.
When does Jade Biosciences next pay dividends?
Jade Biosciences does not currently pay a dividend.
How do I buy Jade Biosciences shares?
To buy shares in Jade Biosciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Jade Biosciences?
As of the previous close price of $12.48, shares in Jade Biosciences had a market capitalisation of $401.86m.
Where are Jade Biosciences shares listed?
Here are the trading details for Jade Biosciences:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: JBIO
What kind of share is Jade Biosciences?
Based on an overall assessment of its quality, value and momentum Jade Biosciences is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Jade Biosciences share price forecast for 2025?
The analyst consensus target price for shares in Jade Biosciences is $2,858.59. That is 22805.39% above the last closing price of $12.48.
Analysts covering Jade Biosciences currently have a consensus Earnings Per Share (EPS) forecast of -$753.41 for the next financial year.
Find out moreWhat is the trend in the Jade Biosciences share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Jade Biosciences. Over the past six months, its share price has outperformed the S&P500 Index by +22.89%.
As of the last closing price of $12.48, shares in Jade Biosciences were trading +45.79% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Jade Biosciences PE Ratio?
The Jade Biosciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $12.48.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Jade Biosciences?
Jade Biosciences' management team is headed by:
- Mark Iwicki - NEC
- Benjamin Dake - PRE
- Timothy Noyes - CEO
- George Eldridge - CFO
- Hunter Gillies - OTH
- Ralph Niven - OTH
- Allison Dorval - IND
- David Grayzel - IND
- Maha Katabi - IND
- Joshua Resnick - IND